Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ECF843 (Lubricin) vs Vehicle in Dry Eye Disease
NCT04391894Phase 2Completed
- Sponsor
- Novartis
- Start
- Oct 2020
- Primary completion
- May 2021
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of recombinant human proteoglycan 4 in dry eye disease (DED) (5 arms), sponsored by Novartis. Primary endpoints: Change From Baseline in Symptom Assessment in Dry Eye (SANDE) Score at 28 days and Change From Baseline in Composite Corneal Fluorescein Staining Score at 28 days. Started Oct 2020; status: completed.
02
Drugs
recombinant human proteoglycan 4
03
Conditions
dry eye disease (DED)
Beyond the preview
Go deeper on NCT04391894.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04391894.